Related references
Note: Only part of the references are listed.Janus kinase inhibitors in autoimmune diseases
John J. O'Shea et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
Luc Van Rompaey et al.
JOURNAL OF IMMUNOLOGY (2013)
JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy
Kris Vaddi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
John J. O'Shea et al.
IMMUNITY (2012)
Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors
Claude Haan et al.
CHEMISTRY & BIOLOGY (2011)
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
Kamran Ghoreschi et al.
JOURNAL OF IMMUNOLOGY (2011)
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes
Richard J. Riese et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2010)
Share Paper
